| Lung
Cancer |
- initial
diagnosis (for example, to evaluate a pulmonary nodule at
least 8 mm up to 4 cm that is indeterminate by chest x-ray
or CT).
- staging
or restaging of non-small cell carcinoma, histologically
confirmed (NSCLC).
|
| Breast
Cancer |
- detection
of locoregional recurrence or distant metastasis (staging/restaging).
The patient has a diagnosis of breast cancer.
- evaluate
treatment response for breast cancer, baseline scan and
during chemotherapy.
|
| Colorectal
Cancer |
- initial
diagnosis (Rare). When PET is ordered for initial diagnosis
of cancer, i.e. before a histologic diagnosis is available,
the conventional clinical and imaging work-up should be
inconclusive and PET findings should have the potential
to determine the exact location for an invasive diagnostic
test or help avoid an invasive diagnostic test.
- staging
and restaging. The patient has history of colorectal cancer,
there is suspicion of local recurrence or metastasis.
|
| Lymphoma |
- initial
diagnosis (Rare). When PET is ordered for initial diagnosis
of cancer, i.e. before a histologic diagnosis is available,
the conventional imaging work-up should be inconclusive
and PET findings should have the potential to determine
the exact location for an invasive diagnostic test or help
avoid an invasive diagnostic test.
- staging
and restaging of Non-Hodgkin’s Lymphoma and Hodgkin’s
disease. Diagnosis is histologically established.
|
| Melanoma |
- initial
diagnosis (Rare). When PET is ordered for initial diagnosis
of cancer, i.e. before a histologic diagnosis is available,
the conventional clinical and imaging work-up should be
in conclusive and PET findings should have the potential
to determine the exact location for an invasive diagnostic
test or help avoid an invasive diagnostic test.
- staging
and restaging (not for exclusive evaluation of regional
nodes) PET is indicated whenever precise staging or restaging
has the potential to alter clinical management.
|
| Head
and Neck Cancer |
- diagnosis
(for example, unknown primary with positive necknode).
- staging
and restaging (excludes thyroid and CNS malignancies).
|
| Cervical Cancer |
- initial
staging
- only covered for staging at initial diagnosis
- CT or MRI abdomen/pelvis must be completed first and show
no extra-pelvic tumor.
|
| Esophageal Cancer |
- initial
diagnosis (Rare). When PET is ordered for initial diagnosis
of cancer, i.e. before a histologic diagnosis is available,
the conventional imaging work-up should be inconclusive
and PET findings should have the potential to determine
the exact location for an invasive diagnostic test or help
avoid an invasive diagnostic test.
- staging.
The patient has been diagnosed with esophageal cancer and
is being evaluated for possible surgery.
- restaging.
The patient has a history of esophageal cancer issuspected
of having recurrence by clinical symptoms or imaging results.
|
| Thyroid
Cancer |
- restaging
of recurrent or residual thyroid cancers of follicular cellorigin.
Previously treated by thyroidectomy and radioiodine abla-tion.
Serum thyroglobulin > 10 NG/ML and NEG. I-131 whole body
scan.
|
| Refractory
Seizures |
- presurgical
evaluation only
|
Dementia
-
CLICK HERE FOR
EVALUATION FORM |
- Alzheimer's disease vs. Fronto-temporal dementia
|
Restaging studies should generally be performed after
completion of treatment. PET in general is covered for the listed
indications if the results of the PET exam could potentially impact
clinical management. Medicare requires the ordering physician to
document in the patient medical record the indication and justification
for ordering a PET study, including a statement of how the PET findings
might impact clinical management. Other indications for PET not
covered by Medicare include: Multiple Myeloma, soft tissue or Bone
Sarcomas, Renal Cell Carci-noma, and others. For a clinical consult
with one of our PET Radiologists, please call (817) 882-3550 and
ask for Dr. Paul Shyn, Dr. Dan Fawcett, Dr. Jay Yaquinto, Dr. Kim
Kuo, or Dr. James David.
Schedule An Appointment Online
Maps & Directions
Contact Us